Biochem Biophys Res Commun

1. SAKTHI P, Arun K, Priya D
   Integrative network pharmacology and molecular simulation analysis reveals the therapeutic potential of Coscinium fenestratum alkaloids against SARS-CoV-2.
   Biochem Biophys Res Commun. 2026;817:153681.
   

   >> Share

   
   

   
   Epidemiol Infect

2. TOZDUMAN B, Gulle BT
   Influenza Vaccination Coverage and Determinants of Vaccination Among Older Adults in Turkey.
   Epidemiol Infect. 2026 Apr 30:1-17. doi: 10.1017/S0950268826101563.
   

   >> Share

   
   

   
   J Gen Virol

3. CHIANG HL, Lin HT, Chen WY, Liang KH, et al
   Broadly neutralizing monoclonal antibodies derived from mRNA LNP immunization exhibit potent neutralizing ability against JN.1, KP.3.1.1 and XEC new Omicron variants.
   J Gen Virol. 2026;107:002251.
   

   >> Share

   
   

   
   J Immunol

4. BENEZECH S, Picq L, Villard M, Rousseaux N, et al
   Single-cell analysis identifies CPT1a-associated metabolic remodeling in human NK cells during COVID-19.
   J Immunol. 2026;215:vkag036.
   

   >> Share

   
   

   
   J Infect Dis

5. O'HALLORAN A, Hood N, Ujamaa D, Merced-Morales A, et al
   Effects of age and birth cohort on influenza A virus subtype-specific hospitalization rates, United States 2010-2025.
   J Infect Dis. 2026 Apr 27:jiag232. doi: 10.1093.
   

   >> Share

   
   
6. ISHIKAWA S, Okada N, Fukui Y, Ueha R, et al
   Respiratory Syncytial Virus-Mediated Gas6/Axl Axis Induces Hyporesponsive Macrophages to Promote Pneumococcal Proliferation in the Nasopharynx.
   J Infect Dis. 2026;233:674-684.
   

   >> Share

   
   
7. ESNEAU C, Boettiger D, Leask S, Bryant NE, et al
   The Pandemic Respiratory Virus Epidemiological Surveillance Trial - A Self-swab Surveillance System for Respiratory Viruses Nested Within FluTracking.
   J Infect Dis. 2026;233:e1031-e1039.
   

   >> Share

   
   
8. KLAASSEN F, Swartwood NA, Chitwood MH, Lopes R, et al
   National- and State-level SARS-CoV-2 Immunity Trends From January 2020 to December 2023: a Mathematical Modeling Analysis.
   J Infect Dis. 2026;233:714-724.
   

   >> Share

   
   

   
   J Virol

9. DAINES R, Sadeyen J-R, Chang P, Iqbal M, et al
   Mapping hemagglutinin residues driving antigenic diversity in H5Nx avian influenza viruses.
   J Virol. 2026 Apr 30:e0009526. doi: 10.1128/jvi.00095.
   

   >> Share

   
   

   
   Lancet

10. DU X, Anderson CS
    Off-target benefits of influenza vaccination in cardiovascular disease - Authors' reply.
    Lancet. 2026;407:1600.
    

    >> Share

    
    
11. FROBERT O, Pedersen IB, Hjelholt AJ, Erikstrup C, et al
    Off-target benefits of influenza vaccination in cardiovascular disease.
    Lancet. 2026;407:1599-1600.
    

    >> Share

    
    

    
    Pediatrics

12. ENGSTROM EE, Kaplan SL, Barson WJ, Lin PL, et al
    Pneumococcal Pneumonia in Hospitalized Children: 2017-2023.
    Pediatrics. 2026;157:e2025073196.
    

    >> Share

    
    
13. KUTZ C, Alarcon-Andrade G, Aguilera E, Garfias C, et al
    Incidence and Severity of Type 1 Diabetes in Children Through the COVID-19 Pandemic in Chile.
    Pediatrics. 2026 Apr 23:e2025072191. doi: 10.1542/peds.2025-072191.
    

    >> Share

    
    
14. JACOBSON KB, Merchant M, Fireman B, Klein NP, et al
    SARS-CoV-2 Vaccination Before and During Pregnancy and Prevention of Infant COVID-19 Infection.
    Pediatrics. 2026 Apr 22:e2025073000. doi: 10.1542/peds.2025-073000.
    

    >> Share

    
    
15. LOWENSTEIN C, Kamdar N, Rehkopf DH
    Trends in Youth Mental Health Among Patients in Family Medicine Practices: 2017-2023.
    Pediatrics. 2026;157:e2025072305.
    

    >> Share

    
    

    
    PLoS Comput Biol

16. MOSS R, Tobin RJ, O'Hara-Wild M, Adekunle AI, et al
    Ensemble forecasts of COVID-19 activity to support Australia's pandemic response: 2020-22.
    PLoS Comput Biol. 2026;22:e1014199.
    

    >> Share

    
    
17. PAMORNCHAINAVAKUL N, Schroeder DC, VanderWaal K
    QoALa: A comprehensive workflow for viral quasispecies diversity comparison using long-read sequencing data.
    PLoS Comput Biol. 2026;22:e1014208.
    

    >> Share

    
    

    
    PLoS One

18. THIPAYAMASKOMON C, Grimaud O, Tattevin P, Lamhaut L, et al
    High-speed trains versus air transport vectors for mass transfers of critically ill patients: The TRANSCOV cohort study.
    PLoS One. 2026;21:e0348090.
    

    >> Share

    
    
19. HU R, Valdivia A, White T, Ju W, et al
    Poldip2 deficiency attenuates lung disease severity in a mouse model of COVID-19.
    PLoS One. 2026;21:e0348065.
    

    >> Share

    
    
20. OKADA Y, Nishiura H
    Changes in life expectancy and life span equality during the COVID-19 epidemic in 2020-22 in Japan.
    PLoS One. 2026;21:e0345579.
    

    >> Share

    
    
21. RODRIGUEZ-CRESPO JJ, Gutierrez-Leon E, Dammann-Beltran P, Seaman-Gomez JA, et al
    Outcomes in acute pulmonary embolism and their association with adherence to international recommendations around COVID-19 pandemic-induced hospital-strain: The experience in a Mexican tertiary care center.
    PLoS One. 2026;21:e0347761.
    

    >> Share

    
    
22. HASHEMPOUR Y, Zazouli MA, Jaafarzadeh N, Valadan R, et al
    Integrated monitoring of enveloped viruses in hospital environments: Detection, persistence, and implications for infection control.
    PLoS One. 2026;21:e0345644.
    

    >> Share

    
    
23. SU B, Sun Z, Chen R, Liu H, et al
    Association between psychological distress, lifestyle and career planning on health-related quality of life among the university students during school closure of COVID-19 pandemic in China.
    PLoS One. 2026;21:e0347032.
    

    >> Share

    
    
24. WANG M, Laison EKE, Philippsen T, Ghaemi S, et al
    Mechanistic modelling of highly pathogenic avian influenza: A scoping review revealing critical gaps in cross-species transmission models.
    PLoS One. 2026;21:e0347929.
    

    >> Share

    
    
25. FATHELRAHMAN E, Mohamed Ali M, Challa TG, Osman R, et al
    Modeling and assessing Highly Pathogenic Avian Influenza (HPAI) spread, epidemiological control measures, and cost.
    PLoS One. 2026;21:e0340004.
    

    >> Share

    
    
26. BASHIR K, Ouedraogo MO, Dharma C, Sobers M, et al
    Strengthening access to and confidence in COVID-19 vaccines among equity-deserving populations across Canada: An exploratory qualitative study.
    PLoS One. 2026;21:e0301953.
    

    >> Share

    
    
27. KO CC, Wu JY, Hung KC, Liao SW, et al
    The impact of COVID-19 vaccination on long-term risk of new-onset atrial fibrillation/flutter after COVID-19 infection: A retrospective cohort study.
    PLoS One. 2026;21:e0348133.
    

    >> Share

    
    
28. LIU C, Yang L, Lei J
    CMAP-Fusion: A cross-modal feature selection and model pruning framework for laboratory and imaging data.
    PLoS One. 2026;21:e0346875.
    

    >> Share

    
    
29. DAS N, Konduru L, Dahia SS, Sagnika S, et al
    The stress reduction potential of Bhagavad Gita and Yoga for healthcare workers during the COVID-19 pandemic: A randomized controlled trial.
    PLoS One. 2026;21:e0347320.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

30. RODRIGUEZ HERNANDEZ CJ, Cruz-Cruz A, Shrestha CL, Terekhova M, et al
    Gingipain proteases from the bacterium Porphyromonas gingivalis confer protection against airway viral infection.
    Proc Natl Acad Sci U S A. 2026;123:e2503100123.
    

    >> Share

    
    
31. HUANG KA, Nguyen HTV, Chen YY, Wu KJ, et al
    Broad neutralization of influenza B hemagglutinin antibodies via receptor mimicry and glycan engagement.
    Proc Natl Acad Sci U S A. 2026;123:e2532989123.
    

    >> Share

    
    
32. ZHANG Y, Wang C, Zheng Y, Chen F, et al
    An Ad5-vectored platform generating self-assembling VLPs elicits potent mucosal immunity against influenza A virus and SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2026;123:e2519857123.
    

    >> Share

    
    
33. DE LACY N, Lam WY, Collins T, Danks D, et al
    A century of suicide: Insights from long-term data in the United States.
    Proc Natl Acad Sci U S A. 2026;123:e2519951123.
    

    >> Share

    
    

    
    Vaccine

34. LIU Y, Jia M, Mu X, Jiang B, et al
    Designing equitable influenza vaccination services for older adults in rural China: A discrete choice experiment.
    Vaccine. 2026;82:128590.
    

    >> Share

    
    
35. SILVA LL, Lopes VDS, da Silva DCB, Nemer CRB, et al
    Global overview of vaccine trust: Evidence from a scoping review.
    Vaccine. 2026;79:128482.
    

    >> Share

    
    
36. JAMES E, Christie S, Boye B, Githieya D, et al
    How to leverage social media to build confidence in COVID-19 vaccines: findings and lessons learned from nationwide campaigns in four countries.
    Vaccine. 2026;79:128475.
    

    >> Share

    
    
37. MALDEN DE, Ackerson BK, Gee J, Peryer MA, et al
    Self-reported reactogenicity of RSV vaccines among older adults: a post-licensure study within a large integrated healthcare system in Southern California.
    Vaccine. 2026;79:128493.
    

    >> Share

    
    
38. FANTIN R, Das S, Loria V, Calderon A, et al
    Hybrid immunity provides stronger protection against SARS-CoV-2 infection than vaccination alone: Evidence from a population-based active monitoring study.
    Vaccine. 2026;79:128506.
    

    >> Share

    
    
39. DENG L, Barton B, Choi P, Clarke L, et al
    Clinical, psychological and quality of life outcomes up to 12-months following thrombosis with thrombocytopenia syndrome after ChAdOx1-S (AZD1222) vaccination in Australia.
    Vaccine. 2026;79:128501.
    

    >> Share

    
    
40. BRIGGS K, Gingerich MC, Gingerich A, Johnson SK, et al
    Intranasal PIV5-vectored SARS-COV-2 KP.2 vaccine protects against homologous and heterologous challenge in mice and hamsters.
    Vaccine. 2026;79:128490.
    

    >> Share

    
    
41. AZEEZ R, Ames SR, Lotoski LC, Winsor GL, et al
    Predictors of SARS-CoV-2 anti-Spike IgG antibody levels following two COVID-19 vaccine doses among children and adults in the Canadian CHILD Cohort.
    Vaccine. 2026;79:128342.
    

    >> Share

    
    
42. ROOYAKKERS A, Ye L, Cahn PE, Ruiz-Palacios GM, et al
    Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.
    Vaccine. 2026;79:128424.
    

    >> Share

    
    
43. STRAUTINS K, Foong R, Carcione D, Spencer P, et al
    Post-licensure safety monitoring of nirsevimab in Western Australia 2024.
    Vaccine. 2026;79:128468.
    

    >> Share

    
    
44. AIZAWA Y, Shobugawa Y, Tachikawa J, Ikuse T, et al
    Effectiveness of the COVID-19 messenger RNA vaccine against symptomatic omicron infection in children aged 6 months to 11 years in Japan.
    Vaccine. 2026;79:128474.
    

    >> Share

    
    
45. LLOYD PC, Shah PB, Zhang HT, Shah N, et al
    Safety monitoring of health outcomes following RSVPreF3 + AS01 and RSVPreF vaccination among Medicare beneficiaries aged 65 years and older in the United States, 2023-2024.
    Vaccine. 2026;79:128459.
    

    >> Share

    
    
46. MADNI SA, Olson CK, Zauche LH, Machefsky A, et al
    Risk of perinatal death and preterm birth among an observational cohort of women vaccinated against SARS-CoV-2 in pregnancy: CDC COVID-19 vaccine pregnancy registry.
    Vaccine. 2026;79:128461.
    

    >> Share

    
    
47. GIOVANATTI A, Shapiro AE
    Anticipating tuberculosis vaccine acceptability in Kenya and South Africa: a narrative review of behavioral and social drivers and strategies to optimize acceptability.
    Vaccine. 2026;79:128457.
    

    >> Share

    
    
48. GUARDALINI LGO, Martins IM, Bernardino TC, Quintilio W, et al
    Non-clinical analysis of virus-like particles (VLP) containing SARS-CoV-2 vaccine antigens.
    Vaccine. 2026;79:128406.
    

    >> Share

    
    
49. DURIER C, Benhamouda N, Besbes A, Lefebvre M, et al
    Ancestral Wuhan SARS-CoV-2 anti-spike CD4(+) T cells predict protection from symptomatic omicron breakthrough infection.
    Vaccine. 2026;79:128425.
    

    >> Share

    
    
50. VISKUPIC F, Wiltse DL, Liebl Z, Kinslow T, et al
    The prevalence and nature of anti-vaccination legislation in ten midwestern states: Implications for public health and policy.
    Vaccine. 2026;79:128452.
    

    >> Share

    
    
51. DRISLANE S, Lake J, Attwell K
    Learning from government communication strategies to promote infant RSV immunisation: A cross-national study of France, Luxembourg, Spain, and Australia.
    Vaccine. 2026;79:128432.
    

    >> Share

    
    
52. CABIESES B, Obach A, Madrid P, Blukacz A, et al
    Mapping the continuum of COVID-19 vaccine acceptance and hesitancy in Chile: Insights from qualitative research among nationals and migrants.
    Vaccine. 2026;79:128433.
    

    >> Share

    
    
53. LU PJ, Hung MC, Srivastav A, Kriss JL, et al
    RSV vaccination uptake by the end of the 2024-25 respiratory virus season among adults aged 60-74 years at increased risk of severe RSV and adults aged >/=75 years.
    Vaccine. 2026;79:128427.
    

    >> Share

    
    
54. JANSSEN RS, Coffman RL
    A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonists.
    Vaccine. 2026;79:128437.
    

    >> Share

    
    
55. IRVING SA, Crane B, Daley MF, Dixon BE, et al
    2023-2024 COVID-19 vaccination coverage in pregnancy in ten healthcare delivery organizations in the United States.
    Vaccine. 2026;79:128441.
    

    >> Share

    
    
56. COSTANTINO V, Notaras A, MacIntyre CR
    Long COVID in children in Australia and the potential impact of vaccination.
    Vaccine. 2026;79:128442.
    

    >> Share

    
    
57. LLANES-KIDDER C, Gaythorpe K, Rawson T
    Sociodemographic factors influencing COVID-19 vaccine uptake and dropout rates in England.
    Vaccine. 2026;79:128477.
    

    >> Share

    
    
58. MCEVOY R, Hervol JR, Zhang Y, Wagner EM, et al
    A modified self-controlled case series on mortality risk following primary series doses of COVID-19 vaccines in U.S. Medicare beneficiaries aged 65 years and older.
    Vaccine. 2026;79:128460.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share